To gain insight into the molecular pathogenesis of the myelodysplastic syndromes (MDS), we performed global gene expression profiling and pathway analysis on the hematopoietic stem cells (HSC) of 183 MDS patients as compared with the HSC of 17 healthy controls. The most significantly deregulated pathways in MDS include interferon signaling, thrombopoietin signaling and the Wnt pathways. Among the most significantly deregulated gene pathways in early MDS are immunodeficiency, apoptosis and chemokine signaling, whereas advanced MDS is characterized by deregulation of DNA damage response and checkpoint pathways. We have identified distinct gene expression profiles and deregulated gene pathways in patients with del(5q), trisomy 8 or À7/del(7q). Patients with trisomy 8 are characterized by deregulation of pathways involved in the immune response, patients with À7/del(7q) by pathways involved in cell survival, whereas patients with del(5q) show deregulation of integrin signaling and cell cycle regulation pathways. This is the first study to determine deregulated gene pathways and ontology groups in the HSC of a large group of MDS patients. The deregulated pathways identified are likely to be critical to the MDS HSC phenotype and give new insights into the molecular pathogenesis of this disorder, thereby providing new targets for therapeutic intervention.
Introduction
The myelodysplastic syndromes (MDS) are a heterogeneous group of clonal hematopoietic stem cell (HSC) malignancies that are characterized by ineffective hematopoiesis resulting in peripheral cytopenias (thrombopenia, leucopenia and anemia) and typically a hypercellular bone marrow. 1, 2 The MDS are pre-leukemic conditions showing frequent progression to acute myeloid leukemia (AML). Approximately 40% of MDS patients develop AML. 1, 2 MDS is one of the commonest myeloid malignancies and is at least as common as AML. 3, 4 The classification of MDS is based on morphologic anomalies according to the French-American-British Cooperative Study Group. 5 More recently, this classification has been modified by the World Health Organization. 6, 7 Patients with refractory anemia (RA) with or without ringed sideroblasts, according to the French-American-British classification, were subdivided based on the presence or absence of multilineage dysplasia. In addition, patients with RA with excess blasts (RAEB) were subdivided into two categories, RAEB1 and RAEB2, based on the percentage of bone marrow blasts. Patients with 420% blasts were classified as AML. MDS patients with o5% bone marrow blasts and an isolated deletion of the long arm of chromosome 5 [del(5q)] were categorized as 5qÀ syndrome, and a new category termed as MDS-unclassifiable was created incorporating patients not fulfilling the other criteria. The main prognostic factors of MDS, for progression to AML and survival, include the number of cytopenias, percentage of marrow blasts and cytogenetic abnormalities. These factors are combined in an International Prognostic Scoring System that distinguishes four subgroups with distinct probabilities of progression to AML and survival. 8, 9 Early MDS (RA) are characterized by an increased apoptosis in the bone marrow, which may in part underlie the ineffective hematopoiesis and peripheral blood cytopenia found in these subgroups. In contrast, in advanced MDS (high-risk MDS), a progressive increase in myeloblasts, coupled with a decrease in apoptosis, and increased genomic instability is observed. 1, 2 Karyotypic abnormalities are reported in about 50% of patients with primary MDS and 80% of patients with secondary MDS. 10 The characteristic MDS abnormalities involve loss of genetic material, whereas balanced translocations are rare. The most common cytogenetic abnormalities in MDS include the del(5q), trisomy 8 and À7/del(7q). 10 Patients with the 5qÀ syndrome, in which the del(5q) is the sole karyotypic abnormality, are characterized by a macrocytosis, anemia, normal or high platelet count and hypolobulated megakaryocytes in the bone marrow and a good prognosis. [11] [12] [13] The presence of À7/del(7q) is associated with a frequent progression to AML, and chromosome 7 abnormalities are an indicator of a poor prognosis in the International Prognostic Scoring System. 8 In comparison, MDS with trisomy 8 typically has an intermediate prognosis;
8 peripheral blood cytopenias are often responsive to immunosuppressive treatment, 14 and have a more favorable prognosis. A number of gene abnormalities have been implicated in the development or progression of MDS, including, for example, mutations in the Ras, p53, RUNX1 and TET2 genes. 15, 16 However, the molecular pathogenesis of MDS remains incompletely understood.
The disease course and prognosis are highly variable in MDS. The majority of MDS patients will succumb to the disease over time, because of infection as a result of neutropenia and/or neutrophilic dysfunction or the development of AML. 1, 2 With the exceptions of lenalidomide, which is effective in MDS with the del(5q) 17 and hypomethylating agents such as azacitidine, which is used to treat advanced MDS and may improve overall survival by several months, 18 there are few effective drug treatments for this disorder. 19 MDS-associated leukemia does not respond well to chemotherapy and patients have a poor prognosis.
1,2 Allogeneic stem cell transplantation remains the only option for curative treatment in MDS, yet is only applicable in 15-20% of all patients. 20 The identification of new targets in MDS for drug treatment is, therefore, of major importance.
Recent studies have identified several core signaling pathways altered in the development of certain solid tumors, including glioblastoma 21 and pancreatic cancer, 22 that greatly further our understanding of the molecular pathogenesis of these malignancies and importantly may represent new targets for therapeutic intervention.
We have chosen to determine deregulated gene expression pathways and ontology (functional) groups in the CD34 þ cells of a large group of patients with MDS to advance our understanding of these disorders.
Materials and methods

Sample collection and cell separation
A total of 183 patients with MDS and 17 healthy controls were included in the study. Classification of MDS patients was according to the French-American-British criteria, 5 with RAEB patients further subdivided into RAEB1 and RAEB2. At the time of sample, 55 patients had RA, 48 RARS, 37 RAEB1 and 43 RAEB2. The MDS patient samples were collected from several centers: Oxford and Bournemouth (UK), Duisburg (Germany), Stockholm (Sweden) and Pavia (Italy). The study was approved by the ethics committees (Oxford C00.196, Bournemouth 9991/ 03/E, Duisburg 2283/03, Stockholm 410/03, Pavia 26264/2002) and informed consent was obtained. Bone marrow samples were obtained and CD34 þ cells isolated from MDS patients and healthy controls. Mononuclear cells were separated using Histopaque (Sigma-Aldrich, Gillingham, UK) density gradient centrifugation, labeled with CD34 MicroBeads, and then CD34 þ cells were isolated using MACS magnetic cell separation columns (Miltenyi Biotec, Bergisch Gladbach, Germany) according to the manufacturer's recommendations. The purity of CD34 þ cell preparations was evaluated with FACS and was X90%.
Affymetrix experiments
Total RNA was extracted using TRIZOL (Invitrogen, Paisley, UK) following the manufacturer's protocol. The quality of the RNA samples was evaluated using Agilent Bioanalyzer 2100 (Agilent Technologies, Santa Clara, CA, USA). For each sample, 50 ng of total RNA were amplified and labeled with the Two-Cycle cDNA Synthesis and the Two-Cycle Target Labelling and Control Reagent packages (Affymetrix, Santa Clara, CA, USA). 10 mg of biotin-labeled fragmented cRNA was hybridized to GeneChip Human Genome U133 Plus 2.0 arrays (Affymetrix), covering over 47 000 transcripts representing 39 000 human genes. Hybridization was performed at 45 1C for 16 h in Hybridization Oven 640 (Affymetrix). Chips were washed and stained in a Fluidics Station 450 (Affymetrix) and scanned using a GeneChip Scanner 3000 (Affymetrix).
Microarray data analysis
Cell intensity calculation and scaling was performed using GeneChip Operating Software. Data analysis was performed using GeneSpring 7.3.1 (Agilent Technologies). The GeneChip Operating software was used to perform quality control after scaling the signal intensities of all arrays to a target of 100. The values obtained for scale factors, background levels, percentage of present calls, 3 0 /5 0 GAPDH ratio and intensities of spike hybridization controls were within the acceptable range for all samples. Affymetrix CEL files were pre-processed using robust multichip analysis. 23 Data from 17 healthy controls were used to obtain patient/control expression ratios. Hierarchical clustering was performed with GeneSpring software using standard correlation. Pathway analysis was performed using Ingenuity Pathway Analysis 7.5 software (Ingenuity Systems, Redwood City, CA, USA) based on the Ingenuity Pathways Knowledge Base, which is the most comprehensive database of biological findings. Gene ontology was performed using the Database for Annotation, Visualization and Integrated Discovery (DAVID). The data discussed in this publication have been deposited in NCBI's Gene Expression Omnibus 24 and are accessible through GEO Series accession number GSE19429 (http:// www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc ¼ GSE19429).
Real-time quantitative PCR
The expression data for selected genes were validated in a subset of MDS patients (n ¼ 12) and controls (n ¼ 11) using realtime quantitative PCR. The b2-microglobulin gene was used to normalize for differences in input cDNA. Pre-developed TaqMan Assays were used (Assays-on-Demand, Applied Biosystems, Foster City, CA, USA) and reactions were run on a LightCycler 480 Real-Time PCR System (Roche Diagnostics, Lewes, UK). Each sample was run in triplicate and the expression ratios were calculated using the DDC T method.
Results
The gene expression profiles of CD34 þ cells obtained from the bone marrow aspirates of 183 MDS patients were compared with those of CD34 þ cells from the bone marrow aspirates of 17 healthy individuals. We identified several genes that were up-or down-regulated in the CD34 þ cells of the majority of the MDS patients. Thirty-five genes were up-regulated with a ratio 42.0 in at least 92 (half) MDS patients (Supplementary Table  S1 ). IMP3 was the most commonly up-regulated gene (130 of 183 patients). Several of the genes commonly up-regulated in the MDS patients included in our study were interferonstimulated genes. IFIT1, IFITM1, IFI44L and IFIT3 were upregulated by more than twofold in at least 60% of the patients (Supplementary Table S1 ). A total of 139 genes were downregulated with a ratio o0.5 in at least 92 MDS patients, including ARPP-21, Gravin/AKAP12, CD24 and LEF1 (Supplementary Table S1 ). The expression levels of five commonly deregulated genes (IFITM1, DLK1, PTHR2, ARPP-21 and Gravin/AKAP12) were validated using real-time quantitative PCR (Supplementary Figure S1) . Real-time quantitative PCR experiments confirmed the up-regulation of IFITM1, DLK1 and PTHR2, and the down-regulation of ARPP-21 and Gravin/ AKAP12 (Supplementary Figure S1) .
Pathway analysis was performed on those genes commonly up-or down-regulated by twofold or more in at least one third of MDS patients (Table 1; Figure 1 ; Supplementary Figure S2 ), using Ingenuity Pathway Analysis software. The most significant deregulated pathway for commonly up-regulated genes was the 'interferon signaling' pathway (Table 1; Figure 1 ). The most significant deregulated pathways for commonly downregulated genes include the 'Wnt/b-catenin signaling' pathway (Table 1) .
To identify deregulated gene pathways and ontology groups in early MDS (RA) and in advanced MDS (RAEB2), differentially expressed genes between the 55 patients with RA and healthy controls (534 genes, P-value o0.05), and between the 43 patients with RAEB2 and healthy controls (4670 genes, P-value o0.05) were obtained and pathway analysis was performed using Ingenuity software (Tables 2 and 3 ; Figure 2 ; Supplementary Figure S3 ). Gene ontology analysis was also performed on these gene lists using DAVID, and the significant main ontology themes for the comparison RA vs healthy controls include 'immune response' and 'apoptosis' (Supplementary Table S2) , and for the comparison RAEB2 vs healthy controls include 'cell cycle' and 'DNA repair' (Supplementary Table S2 ). 
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We determined whether a distinct gene expression profile was associated with specific cytogenetic groups. We investigated differences in gene expression between the 29 MDS patients with a del(5q), five MDS patients with À7/del(7q) and five MDS patients with þ 8. We applied ANOVA using 0.05 P-value cutoff and Benjamini-Hochberg multiple testing correction, and 290 significantly different probe sets were identified. Hierarchical clustering performed using these 290 probe sets could separate the MDS patients into different clusters according to their cytogenetic group (Supplementary Figure S4) . Leave-oneout cross-validation classified all samples correctly.
Differentially expressed genes between patients with del(5q) and healthy controls (507 genes, P-value o0.001), between patients with À7/del(7q) and healthy controls (353 genes, P-value o0.05) and between patients with þ 8 and healthy controls (430 genes, P-value o0.01) were obtained and pathway analyses were performed (Tables 4-6 ). Gene ontology analysis was also performed on these gene lists using DAVID (Supplementary Table S2 ) and the significant main ontology themes for the comparison of del(5q) vs healthy controls include 'chromatin assembly' and 'translation,' for the comparison of À7/del(7q) vs healthy controls include 'activation of JNK activity' and 'signal transduction' and for the comparison of þ 8 vs healthy controls include 'immune response' and 'leukocyte activation.'
Discussion
The identification of genes and gene pathways deregulated in cancer can lead to a better understanding of the molecular pathogenesis of the disease and identify new targets for Genes in regular font are expressed at lower levels in RA compared with healthy controls, whereas genes in bold font are expressed at higher levels in RA compared with healthy controls. Abbreviation: RAEB, refractory anemia with excess blasts. Genes in regular font are expressed at lower levels in RAEB2 compared with healthy controls, whereas genes in bold font are expressed at higher levels in RAEB2 compared with healthy controls. Multiple deregulated pathways have been identified in MDS. We have shown that the 'interferon signaling' pathway is the most significantly up-regulated pathway in MDS, with multiple genes in this pathway, including STAT1, IRF9, IFIT1 and IFITM1, showing up-regulation in MDS. IFN-g, which is overexpressed in the bone marrow of MDS patients, 25 has been shown to exhibit a strong inhibitory effect on hematopoietic progenitor and stem cells. 26, 27 We have earlier reported the up-regulation of several interferon-stimulated genes in MDS 28 and this present Genes in regular font are expressed at lower levels in del(5q) compared with healthy controls, whereas genes in bold font are expressed at higher levels in del(5q) compared with healthy controls.
Deregulated pathways in myelodysplastic syndromes
A Pellagatti et al study confirms and extends these earlier observations. We suggest that the up-regulation of interferon-stimulated genes and of the interferon signaling pathway is a major feature of MDS and may be responsible for some of the hematological characteristics of MDS, including cytopenias. Megakaryocytic differentiation is frequently defective in MDS; thrombocytopenia occurs in about 50% of patients and is a major cause of morbidity and mortality. 1, 29 Thrombopoietin and its receptor (TPOR) have an important function in maintaining production of controlled numbers of megakaryocytes and platelets. 30 Moreover, it has recently been shown that thrombopoietin signaling has a function in HSC self-renewal. 31 Intriguingly, 'thrombopoietin signaling' was the second most up-regulated pathway in MDS, with several genes in this pathway, including TPOR, STAT1 and SOS1 showing up-regulation. Up-regulation of the thrombopoietin pathway in MDS represents a possible mechanism for the observed megakaryocytic abnormalities in MDS. The up-regulation of the interferon and thrombopoietin signaling pathways may relate to a bone marrow compensatory reaction to a fundamental defect in these pathways.
One of the most significantly down-regulated pathways in MDS was the Wnt canonical pathway. Deregulation of this pathway has been implicated in the pathogenesis of several different types of human cancer, including leukemia. In contrast to our findings in MDS, the Wnt pathway has been shown to be up-regulated in chronic myeloid leukemia and AML. 32, 33 The Wnt pathway has a critical function in the regulation of the self-renewal of HSC, 34 and we speculate that down-regulation of the Wnt pathway in MDS may lead to defective self-renewal of HSC in this disorder.
To better understand disease progression in MDS, we sought to identify genes and deregulated gene pathways in early and advanced MDS. There is mounting evidence, such as the presence of autoreactive T-cell clones and increased levels of preapoptotic cytokines, suggesting that immune deregulation, especially in early MDS, results in an autoimmune process leading to ineffective hematopoiesis and bone marrow failure, whereas advanced MDS is characterized by the immune evasion and selective growth advantage of the malignant clone. 35, 36 In accord with this hypothesis, we have found that among the most significantly deregulated gene pathways in RA are 'immunodeficiency signaling,' 'B-cell receptor signaling,' 'IL4 signaling' and 'chemokine signaling.' The 'primary immunodeficiency signaling' pathway was the most significantly deregulated pathway in RA. This pathway was also deregulated in RAEB2, but with a lower significance. Deregulation of the 'B-cell receptor signaling' pathway in RA is in accord with earlier observations from our group and others that reduced expression of genes involved in B-lymphocyte development is a feature of MDS. 28, 37 It has recently been shown that T-Regulatory cells in early MDS, in contrast to advanced MDS, have a reduced ability to suppress immune responses and, through reduced expression of CXCR4, impaired bone marrow trafficking. 35 In agreement with these findings, we found that chemokine signaling through CXCR4 was deregulated in RA, with CXCR4 being down-regulated in RA by approximately 50% compared with healthy controls in our study. Genes in regular font are expressed at lower levels in À7/del7q compared with healthy controls, whereas genes in bold font are expressed at higher levels in À7/del7q compared with healthy controls.
Table 6
Top 10 deregulated pathways in +8 compared with healthy controls Genes in regular font are expressed at lower levels in +8 compared with healthy controls, whereas genes in bold font are expressed at higher levels in +8 compared with healthy controls.
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Early MDS is characterized by a high level of apoptosis and in accord with this, we found that the apoptosis signaling pathway was one of the most significantly deregulated pathways (upregulated) in RA, but not in RAEB2. It is well recognized that there is a higher bone marrow apoptotic index in the bone marrow of low-risk MDS patients compared with high-risk MDS and MDS-AML. [38] [39] [40] Advanced MDS is characterized by high levels of genomic instability with a concomitant increase in cytogenetic abnormalities in comparison with early MDS. DNA damage facilitates activation of the DNA damage response (DDR) and DNA damage checkpoint pathways, which can then lead to cell cycle arrest, apoptosis, repair or cell senescence. The study of advanced solid tumors has shown that once DNA damage has occurred in genes having a crucial function in the DDR, the DNA damage checkpoint pathway is compromised or inactivated and the cells show increased genomic instability and acquire a growth advantage leading to malignant transformation. 41 Intriguingly, the most significantly deregulated gene pathways in RAEB2 in our study concern the DDR and checkpoints, including, for example, 'CHK proteins in cell cycle checkpoint control,' 'ATM signaling,' 'BRCA1 in DDR,' 'G2/M DNA damage checkpoint regulation' and the 'mitotic roles of polo-like kinase (PLK)' pathways, with most of the significantly deregulated genes mapping to these pathways showing down-regulation in RAEB2 compared with healthy controls. For example, PLK4 mapping to the 'mitotic roles of PLK' pathway is down-regulated in RAEB2 by approximately twofold. Plk4 haploinsufficiency has been shown to cause mitotic infidelity and carcinogenesis.
42 CHK1 is also a haploinsufficient tumor suppressor, 43 is an important component of DDR pathways 44 and is down-regulated in RAEB2 by approximately twofold. Interestingly, MDS-derived cell lines (MDS-related AML) have been shown to exhibit defects in their capacity to mount a checkpoint response. 20 A recent study concerning the identification of deregulated gene pathways in AML has similarly shown the down-regulation of several DDR and checkpoint signaling pathways in AML.
32 RAEB2 is clearly closely related to AML and both disorders seem to share a similar deregulation of the DDR and checkpoint signaling.
The efficient repair of damaged DNA is critical for the maintenance of genome stability and cell survival. 45 Several of the genes mapping to the DDR pathways that we have shown to be down-regulated in RAEB2, for example RAD51 and BRCA2, have an important function in this process. We have shown that RAD51, which mediates homologous recombination repair of DNA double-strand breaks, is down-regulated in RAEB2 by 4twofold compared with healthy controls. Repression of RAD51 gene expression has been described in some tumors and is associated with genomic instability. 46, 47 Intriguingly, several genes, which when mutated give rise to Fanconi anemia, a chromosomal instability disorder with an increased incidence of MDS, 48 are down-regulated in RAEB2, including FANCA and FANCD2. The repression of DNA repair and checkpoint components in RAEB2 would suggest that the clonal MDS cells would accumulate and/or mis-repair DNA strand breaks. We suggest that the increased genomic instability that characterizes RAEB2 may be associated with these abnormalities.
The 'cell cycle' was the most significantly deregulated ontology/functional group in RAEB2 and several of the most significantly deregulated pathways concern the cell cycle. The overall expression pattern suggests that the RAEB2 patients' CD34 þ cells are proliferating less actively than the controls. The down-regulated genes include known E2F targets such as cyclin E, as well as other markers of proliferative index (such as CDC2/CDK1 and cyclin B) and topoisomerase II, which is normally expressed only in the S and G2 phases. However, the interpretation of these data is complex as we also observe up-regulation of the proto-oncogenes c-jun 49 and CREB 50 and down-regulation of RB1, a negative regulator of the cell cycle, 51 in these pathways in RAEB2. The proliferative index of advanced MDS is uncertain, with some studies showing a decreased proliferative rate and others an increased proliferative rate, compared with early MDS. [52] [53] [54] Our data support a defect in regulation of the cell cycle in advanced MDS. The downregulation of several pathways involving the cell cycle in AML, including cell cycle regulation by BRCA1 and CDC25, has also recently been shown. 32 The del(5q) is the most commonly reported deletion in de novo MDS and is found in 10-15% of all patients. 12 Trisomy 8 and À7/del(7q) are also among the most frequently reported karyotypic abnormalities in MDS. 55 The association of karyotypic abnormalities with some particular clinical features of MDS suggests specific functions in the pathogenesis of MDS. 8, 56 Indeed, the clinical behavior of patients with del(5q), þ 8 or À7/del(7q) is different. 8, 56, 57 In our study, hierarchical clustering grouped patients with a del(5q), trisomy 8 or À7/del(7q) into distinct clusters. The demonstration that each of these major karyotypic groups has a particular gene expression profile suggests a common underlying pathophysiologic basis to each disease group. Moreover, our study identified deregulated gene pathways for MDS defined by del(5q), trisomy 8 or À7/del(7q).
Strikingly, the 10 most significantly deregulated gene pathways in trisomy 8 MDS in our study are associated with the immune response, including 'immunodeficiency signaling,' 'B-cell receptor signaling,' 'antigen presentation,' 'CTLA4 signaling in cytotoxic T lymphocytes' and 'T-cell receptorsignaling' pathways. Moreover, 'immune response' was among the most significant gene ontology/functional groups in trisomy 8 MDS identified by our study. These data are in accord with an earlier microarray study by Chen et al. 58 showing that multiple immune and inflammatory response genes are dysregulated in trisomy 8 CD34 þ cells; for example TGFBR3, MAF and IGF1 were found to be up-regulated in both studies. Trisomy 8 MDS has been earlier associated with oligoclonal T-cell expansion, suggestive of an antigen-driven T-cell pathophysiology, and some patients' T-cell clones are specifically cytotoxic for trisomy 8 cells compared with normal cells from the same individual. 59, 60 These results are consistent with an immune system function in the development of pancytopenia in trisomy 8 MDS. 58 Thus, an important role for the immune system in trisomy 8 MDS has been suggested by several groups and our gene expression and deregulated pathway data strongly support and extend this proposal.
The most significantly deregulated gene pathways in del(5q) MDS in our study include 'Wnt/b-catenin signaling,' 'integrin signaling' and 'cell cycle regulation.' We have earlier shown that patients with the 5q-syndrome show deregulation of similar gene pathways. 61 Moreover, 'translation' and 'chromatin assembly' were among the most significantly deregulated ontology groups in del(5q) MDS. Interestingly, marked deregulation of ribosomal-and translation-related genes in patients with the 5q-syndrome has been shown by our group. 62 Multiple pathways that have an important function in cell survival, differentiation, apoptosis and growth [63] [64] [65] [66] were significantly deregulated in À7/del(7q) MDS, including SAPK/JNK, NF-kB, PI3K/AKT and ceramide signaling pathways. Interestingly, CK2, an enzyme with a master regulatory function in Wnt and NF-kB signaling, is up-regulated in À7/del(7q) MDS by 4twofold. Overexpression of CK2 has been shown to promote tumorigenesis and it has been suggested that inhibiting CK2 could be useful in treating cancer. 67 R-Ras2 (TC21), a member of the Ras superfamily of GTP-binding proteins, 68 is also upregulated in MDS with À7/del(7q) and is involved in several of the deregulated pathways in this karyotypic group. R-Ras2 was up-regulated by 4fourfold in MDS with À7/del(7q), in contrast to trisomy 8 and 5q-MDS patients. R-Ras2 has an important function in tumorigenesis and cell growth regulation. 69 The R-Ras2 oncogenic signals are mediated through the PI3K/Akt and NF-kB signaling pathways, both of which are significantly deregulated in MDS patients with À7/del(7q) in our study. Intriguingly, four pathways involving the retinoid X receptor (RXR) and LXR system, 'LXR/RXR activation,' 'FXR/RXR activation,' 'TR/RXR activation' and 'PPAR signaling' were also deregulated in À7/del(7q) MDS. Patients with À7/del(7q) have a poor prognosis and we suggest that deregulation of survival pathways may have an important function in the pathogenesis of this MDS subgroup.
Importantly, many of the deregulated pathway data generated in this study are in accord with the known biology of MDS, and significantly further our understanding of these processes. Furthermore, the significant degree of overlap within and between the pathway and ontology tools used suggests that the deregulated pathways and functional groups identified are critical in the molecular pathogenesis of MDS.
On the basis of our observations, we suggest a model for MDS in which immune deregulation and activation of apoptosis pathways are characteristic of early MDS cells, consistent with clinically observed ineffective hematopoiesis. Subsequently, disruption (down-regulation) of the DNA damage checkpoints in advanced MDS results in an increase in the error rate of DNA repair with a concomitant increase in genomic instability, leading to evolution to AML. This is the first study to determine deregulated gene pathways and ontology groups in the HSC compartment of a large group of patients with MDS. The deregulated pathways identified are likely to be critical to the MDS HSC phenotype and give important new insights into the molecular pathogenesis of this disorder, thereby providing new targets for therapeutic intervention.
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